Life Sciences Archive » July, 2021

Life Sciences - July, 2021

328 articles

• Pa. Health Network Says Virus Losses Covered By Policy
• J&J Wins Ill. Talc Cancer Trial Despite Contempt Finding
• Inovio Investors Move For Cert. In COVID-19 Vaccine Suit
• 6th Circ. Backs Mich. Cannabis Co. Owner's 15-Year Sentence
• Anthem Sued Over Alleged Refusal To Cover Spinal Device
• FTC Drops AndroGel Antitrust Case Against AbbVie
• McKesson Wants Prescription Data In Cherokee Opioid Case
• Illinois Hospitals' Merger Would Stifle Competition, Suit Says
• Australian Judge Makes Bold Patent Leap For AI Inventions
• Ashby & Geddes' Appeal In Del. Bankruptcy Fee Row Tossed
• Texas Pharmacist's FCA Suit Against Walgreens Thrown Out
• Health Hires: Polsinelli, Buchalter, Allen & Overy
• Biggest Merger Review Developments Of 2021 So Far
• A Potential Shift In Antitrust Deferred Prosecution Agreements
• Court Sets Terms For Pfizer Damages Over Axed Lyrica IP
• Imerys Ch. 11 Tort Group Delays J&J Talc Claim Spinoff Fight
• McKinsey Opioid MDL Has A Need For Speed, Judge Says
• IP Forecast: Fed. Circ. To Mull Narcan Patents
• Regeneron Investor Sues Execs, Alleging Kickback Scheme
• Purdue Pharma Gets OK For $22M Worker Bonus Program
• 11th Circ. Tosses Ala. Dental Board's SmileDirect Appeal
• Deals Rumor Mill: Baxter International, Didi Global, Nanosys
• Novartis Cancer Drug Suits Too Few To Centralize, JPML Told
• Senate Panel OKs Antitrust Package Aimed At Drug Pricing
• WTO Sees Trade Rebound Hinging On Vaccine Rollout
• Will You Be Ready If Your Class Action Goes To Trial?
• Biden Admin. Agrees To Crack Down On Upwind Air Pollution
• JPML Urged To Consolidate Weight-Loss Drug Cancer Suits
• Sustainable Biomanufacturing Co. Grabs $100M In Series B
• Three Firms Fined £100M For Overpriced Thyroid Drug
• Opioid Distributors Pin Blame On Others As W.Va. Trial Ends
• Endo, Arnold & Porter Accused Of Cover-Up In Opioid MDL
• Vaxart Suit Turns 'Mundane To Nefarious,' Del. Judge Told
• In Praising O'Malley, Attys Call For District Judge To Fill Seat
• McKinsey Says Cherokee Opioid Suit Can't Go To State Court
• 'Momentous Day' As FDA OKs 1st Interchangeable Biosimilar
• Agenus Investor Sues In Del. Chancery Over Option Awards
• 3 Firms Seek $1.3M In Fees From Zynerba CBD Gel Settlement
• House Subcommittee Asks J&J About Talc Bankruptcy Plans
• P&G Seeks To End Crest Charcoal Toothpaste Class Action
• Amgen's Psoriasis Drug Patents Are Valid, NJ Court Told
• Tide Is Turning Against FCA Case Dismissals
• Law Firms, Know Who's Responsible For Your Cloud Security
• McCarter & English Keeps Win In $860K Fee Suit
• Imerys Seeks Talc Indemnification From Johnson & Johnson
• Houston Energy Exec Pleads Guilty In $317M N95 Scam
• 4 Key Details As Opioid Liability Trial Concludes In Calif.
• 'Mountainous' Opioid Shipments Fed Crisis, Judge Told
• Monsanto Hit With $185M Verdict Over PCB Brain Damage
• FCA Overhaul Bill May Miss Mark On Reining In Fraudsters
• That's A Rap: Shkreli's Wu-Tang Album Sold To Cap Judgment
• Illumina Wants Extra Witnesses For FTC Merger Challenge
• Bio-Rad And 10X Agree To End Patent War
• Benefits For Law Firms Venturing Into New Services
• Arthrex Asks To Fight PTAB Ax On Other Grounds On Remand
• Why Bypass Continuation Is Best For Nat'l Phase Patent Entry
• Johnson & Johnson Held In Contempt In Illinois Talc Trial
• Look To Canada For Cheaper Drugs, Sens. Urge Biden Admin.
• Philips Faces Class Suits Over Recalled CPAP Sleep Devices
• Judge Urged To Rethink Ruling Perrigo Hid $1.9B Irish Tax Bill
• Purdue Pharma Reports Glowing Vote Results For Ch. 11 Plan
• McKinsey Sued For Opioid Effect On W. Virginia Addicts' Kids
• Biotech Co. Can't Arbitrate $881M Cannabinoid IP Fight
• Mall Developer's Asbestos Caused Cancer, Calif. Judge Told
• Takeda Beats Antitrust Claims In Heartburn Drug Patent Fight
• DEA Should Allow Psychedelic Therapy, 9th Circ. Told
• Review Group Slams 'Specious' Sun Pharma Skin Drug Patent
• Hologic Gets Minerva Patent Axed Just Before Del. Trial
• Bipartisan Senator Group Wants False Claims Act Tweaks
• Pfizer, Mylan Beat EpiPen Antitrust Suit, For Now
• SmileDirect Tells 9th Circ. Dental Board Fears Shakeup
• PBM Group Asks 8th Circ. To Revive ND Preemption Row
• Price-Fix 'Common Thread' Links Glenmark To Teva, DOJ Says
• NM Appeals Court Backs Award Of Medical Pot License
• Quartet Of Life Sciences Cos. Prepare For $526M In IPOs
• New FTC Mergers Approach Raises Risks For Buyers, Sellers
• Massage Oil Co. Drops Indemnity Bid In Class Action Fight
• DOJ Fights Walmart's Opioid Challenge At 5th Circ.
• Embracing ESG: Exelon GC Talks Diversity Initiatives
• Buchalter Adds 2 Attorneys To Orange County Office
• Allergan Hits Generic Cos. With Patent Suits Over Viberzi
• 3 Firms Sculpt PerkinElmer's $5.25B Buy Of Life Sciences Co.
• The Law360 400: Tracking The Largest US Law Firms
• Where Have All The Associates Gone?
• US Drops 5 Visa Fraud Suits Against Chinese Scholars
• Opioid Wholesalers, W.Va. Gov'ts Set To Wrap Bellwether
• Cannabis Bill Roundup: Amazon Becomes Pot Lobbyist
• Regeneron 'Kickbacks' Fueled Blockbuster Profits, Suit Says
• Shuttered Mo. Medical Pot Co. Ordered To Pay Back Investors
• Product Liability Regs, Bills To Watch In The 2nd Half Of 2021
• FCA Relator Pursuit Of DOJ's Declined Cases Is Vital
• 3rd Circ. Affirms Win For Novo Nordisk On Age Bias Suit
• UK Litigation Roundup: Here's What You Missed In London
• End Roe V. Wade, Justices Urged As Abortion Battle Begins
• Dems Want Social Media Cos. Liable For Vax Misinformation
• Gilead Must Foot $1.8M Bill For 'Egregious' Litigation Conduct
• Chinese Medical Co. Beats Sleep Apnea Trade Secrets Fight
• EU Deepens Probe Of Illumina's $8B Cancer Detection Deal
• DC Circ. Affirms FDA Fees, Premarket Review Of Pipes, Cigars
• CR Bard Nets 2 Wins, 1 Loss In Faulty IVC Filter Suits
• Drugmaker Acer To Pay $8.35M To End Investor Suit
• Philly DA Slams Opioid Settlement As A Sellout For City
• Attys Seek $11.5M For Fighting Fresenius' 'Stalingrad' Defense
• Anticipating The FDA's Shift Away From Emergency Approvals
• Endo Offers To End Tenn. Opioid Baby Suit For $35M
• Judicial Nominees Advance As GOP Knocks 1st Circ. Pick
• House OKs Bill To Join Health Coalition Funding Vaccines
• Jury Hits Novartis With $178M Verdict In Drug Patent Fight
• Kirkland-Led Insurer Ryan Specialty Lands $1.3B IPO
• Revamping Law Firm Marketing Lists — With Partner Buy-In
• Pfizer Unit Loses Appeal In Vaccine Fight With Merck Branch
• Pump Maker Loses Bid To Appeal Roche's UK Patent Win
• Despite Fanfare, $26B Opioid Offer Far From Finish Line
• Daiichi Sankyo Unit Seeks $178M From Novartis As Trial Ends
• Illumina 'Wasting Court Time' With Deal Overtures, FTC Says
• J&J Settles Pfizer's Antitrust Suit Over Remicade Biosimilar
• Health Co., Investor Ink $15.3M Deal To End DOJ Fight
• Flopped COVID Drug Trial Spurs Corporate Waste Suit
• 5th Circ. Mulls New Trial Bid In Sanofi Chemo Bellwether
• UMass Tells Fed. Circ. To Wipe Out L'Oreal's Skincare IP Win
• Shook Hardy Names 3 New Office Leaders Amid Expansion
• Takeda 401(k) Suit 'Squeaks By' Dismissal, Judge Says
• Pharmacist Gets More Prison In Deadly Meningitis Outbreak
• AGs Unveil $26B Global Opioid Deal With J&J, Distributors
• NY Official Tells Jury Public Was Taught To Treat Opioid ODs
• House Hearing Slams Opacity Of FCC Spectrum Rulemaking
• Opana Sales Calls Didn't Cause Rx Rise, Economist Testifies
• Utah Medical Pot Licenses Unlawfully Awarded, Suit Says
• House Votes To Restore FTC Disgorgement Authority
• 'Lives Are On The Line,' Say GOP Reps Pushing Biden On Pot
• Fidelity Dodges Pfizer Retiree's Suit Over Lack Of Tax Advice
• DC Circ. Won't Add To Novo Nordisk Whistleblower's Payout
• NY Urges Justices To Pass On State Opioid Tax Challenge
• The Murky World Of Legal Rankings Gets Some Clarity In NJ
• Judge OKs Consolidation Of CVS Drug Pricing Suits
• Examiner Clears Sacklers Of Influencing Purdue's Board
• Baker Botts Adds Tech Partner To Dallas Corporate Practice
• Drug Distributors Strike $1.1B Opioid Deal, Exit NY Trial
• Husch Blackwell Moves Into New England With 11-Atty Firm
• J&J, Distributors Set To Unveil Opioid Deals Worth $26B
• US Trustee Flags Sacklers' Release, Atty Fees In Purdue Plan
• Novartis IP Expert Slams Rival's Royalties Estimate At Trial
• FDA-Nixed Language Can Be In Drug Promos, Expert Testifies
• Galderma Gets PTAB To Invalidate Wrinkle Treatment Patent
• Talc Plaintiffs' Attys Fume At Idea J&J Might Use Ch. 11 Tactic
• Optical Lab Wants Black Ex-Worker's Bias Suit Tossed
• Indiana Univ. Can Keep COVID Vax Requirement During Suit
• FDA Q2 Warning Letters Show Agency Enforcement Priorities
• Embracing ESG: Cigna Counsel Talks Employee Wellness
• Ex-FDA Senior Regulatory Counsel Joins Foley Hoag In DC
• Novartis' Expert Denies Rival Atty's Plagiarism Claim In IP Trial
• Invisalign Maker, Investors Hatch $16M Deal In IP-Linked Suit
• AstraZeneca's Anemia Drug Sees Setback At FDA Committee
• Bankruptcy Cases To Watch In The Second Half Of 2021
• McKinsey Says Cherokee Opioid Suit Destined For MDL
• Apotex Pays Texas $26M To End Medicaid Fraud Probe
• POP Won't Review PTAB Institution Rulings On Align Patents
• Hybrid Work Models Are Key To Gender Parity In Law Firms
• Perrigo's Investor Form In $1.9B Tax Row Ruled Misleading
• Pa. Judge Defends Financial Discovery In Vein Filter Litigation
• Jones Day Adds Consumer Products Counsel In Miami
• UK Litigation Roundup: Here's What You Missed In London
• Novartis' Expert Accuses Rival's Atty Of Gaslighting In IP Trial
• Opioid Cos. Defied FDA Promo Limits, Ex-Commissioner Says
• McKesson's 'Abusive Discovery' Is FCA Dismissal Ploy: DOJ
• Naturopathic Doc Sold Fake COVID Vaccine Cards, Feds Say
• J&J Sued Over Carcinogen After Sunscreen Recall
• Club Operator's $420M Float Leads Busy Day Of IPOs
• IP Forecast: Alsup To Hear Finjan's Fee Fight With Juniper
• PTAB Will Review Alzheimer's Treatment Patent
• Pfizer And EpiPen Consumers Reach $345M Deal
• Digging Into FCA Stats: Litigation's Return On Investment
• Sea Change In Drug Assistance Programs May Be On Horizon
• 6 Things To Know About Cannabis M&A Transactions
• USPTO Says US Inventor's Fintiv Loss Also Hurts Tech Suit
• Biopharma Co. Says Unnamed Person Is Impersonating CEO
• A Practical Metric For Annual Patent Filing Targets: Part 3
• Fed. Circ. Calls For New Damages Trial In Pet IP Row
• Novartis Shorted Rival Up To $47M In IP Royalties, Jury Told
• Loeb & Loeb Swipes PTAB Pro From Womble Bond
• Perrigo, Investors Must Go To Trial Over Co.'s $1.9B Tax Bill
• AstraZeneca Wins Final Nod For $39B Alexion Deal
• Suzanne Somers' Sabotage Trial Against QVC Set For Fall
• 3 Keys To Winning Your Next Oral Argument
• Digging Into FCA Stats: A Decade of Litigation Trends
• 7th Circ. Orders Judge Consider Copay Groups In Opana Cert.
• Pfizer Unit Fights Loss To MSD In Pneumonia Vaccine IP Case
• WHO Committee Wants Global Rules On Gene-Editing Patents
• Top Senate Dems Admit Pot Legalization Push A Long Shot
• Former In-House Global IP Head Pivots To Smith Gambrell
• Dickinson Wright Adds 7 Attys To IP Practice
• 3 Takeaways From Senate Dems' Pot Legalization Bill
• DuPont, Others Ink $50M Del. Deal Over 'Forever Chemicals'
• Judge Tells Attys IP Testimony Is 'Dense,' But 'It's Your Case'
• Traps, Thickets And Hops: Sens. Pin Down Drug Price Culprits
• J&J Win In Asbestos-Talc Case Meets Skeptical Appeals Panel
• Opioid Rx Rise Can't Be Pinned Only On Ads, Prof Says
• We Can Dance If We Want To, We Can Put Our Patents Online
• Doctors Were Engine Of Opioids' Rise, Cos. Tell Jury
• Cherokees Say McKinsey Opioid Suit Shouldn't Head To MDL
• PTAB Won't Review Amgen Patent On Chemotherapy Drugs
• What To Watch As EU Clinical Trial Compliance Changes
• Teva Says Rival Hoarding Drug To Slow Generic Development
• Digging Into FCA Stats: In-House Litigation Budget Insights
• PE-Backed Waterworks Co. Leads 4 IPOs Likely To Top $1.2B
• Israeli Co. Fights Arbitration Of $16M Sex Discrimination Suit
• Pharma Co. Asks 9th Circ. To Revive Opioid Coverage Dispute
• J&J, Rite Aid, CVS Talc Suit Remanded To NY State Court
• Fed. Circ. Told 10X's IP Loss At Odds With Minerva Ruling
• Keys To Efficient And Accurate Doc Review For E-Discovery
• Roche Invalidates Competitor's Insulin Pump IP In UK Suit
• Wilson Sonsini Adds Ex-Shearman & Sterling Atty In Texas
• Meet JPML's Favorite Judge, Tasked With New Opioid MDL
• Opioid Cos.' Sales Training Misled Doctors, Jury Hears
• Daiichi Sankyo Unit Says Rival Infringed IP As Trial Opens
• Insurer Leads Flood Of 14 IPO Prospects That Could Top $3B
• Chickasaw Push Back On Arbitration Ruling In Drug Dispute
• Venable Adds 5 Intellectual Property Partners From Dentons
• HHS Funding Bill Passes Through House Subcommittee
• US Trustee Calls For Hold On $29M In Purdue Bonuses
• Avoiding Antitrust Issues In Search Term Ad Agreements
• Embracing ESG: Raytheon GC Talks Climate Change
• Insulin Drug Makers Shed Antitrust Claims In MDL
• Kirkland Nabs Litigator From Orrick In DC
• Top New Jersey Cases Of 2021: A Midyear Report
• Allergan Strikes $130M Deal Over Drug Price-Fixing Claims
• Humanigen, Savant Dispute Over Drug Development Narrowed
• Shaming Doctors Was Vital To Opioid Adoption, NY Jury Hears
• Gov't Can't Ditch Akebia's Suit Over Kidney Drug Coverage
• Drug Prices Are Prime Target In Biden's Competition Order
• Cannabis Bill Roundup: Missouri Gov. Nixes Pot Tax Reform
• FDA Head Seeks IG Probe Of Biogen Alzheimer's Drug Talks
• Big Pharma's Stock Spending Exceeds R&D, Dems Say
• Health Hires: SCAN Group, AgomAb
• Jury Awards Utica Mutual $10.9M In Asbestos Reinsurance Rift
• Changes In Over-The-Counter Drug Regulation Are Flawed
• J&J Can't Block Deposition Of Media Rep In Talc Cancer Suit
• 9th Circ. Won't Revive Ex-Merck Worker's Drug Kickback Suit
• Bayer, Janssen Duck Louisiana Blue Cross' Xarelto Claims
• Pa. Cases To Watch In 2021: Midyear Report
• Former Dow Counsel, Ex-EPA Exec Joins Barnes & Thornburg
• High Court Arthrex Remedy Should Concern Congress
• Atty Joins Gordon & Rees As Partner In NJ And NY Offices
• Taxation With Representation: Gibson, Latham, Simpson
• Generics, Retailers Escape Zantac MDL With Preemption
• Real Estate Rumors: Foundry, Raytheon, RAS Development
• EPA Revokes Allied BioScience SurfaceWise2 Spray Approval
• Product Liability Cases To Watch: Midyear Review
• Sweeping Biden Order Aims To Attack Lack Of Competition
• Evoqua To Pay $16.7M To End Investors' Suit Over $500M IPO
• Opioid 'Gremlins' Torment Patients, New York Jury Hears
• Alere Agrees To Pay $38.8M Over Blood Monitoring Device
• St. Jude Medical To Pay $27M To End Faulty Heart Device Suit
• USPTO Opens Floodgates To Patent Eligibility Feedback
• Stryker Cos. Will Pay $15M To End Medical Device Patent Suit
• Fed. Circ. Appears Split On Novartis' MS Drug Patent
• IP Forecast: Daiichi Sankyo Unit Takes Drug Rival To A Jury
• Avanos To Pay $22M To Settle Surgical Gown Criminal Charge
• 5th Circ. Backs Broad DOJ Power To Toss FCA Suits
• Alzheimer's Drug Getting Label Revision, Biogen Says
• 5 Firms Steer PE Sale Of €1.25B Genetic Testing Co
• Nationwide Sues To Avoid Defending Vitamin Co. In TM Fight
• Deals Rumor Mill: Sydney Airport, Tencent, Ottobock
• Withers Picks Red-Hot Kendall Square For New Mass. Office
• Responding To Novelty Rejections After Recent PTAB Ruling
• Rising Star: Covington & Burling's Tyler Evans
• 1-800 Contacts Ruling Illustrates IP Hurdle For Antitrust Cases
• 5 Firms Sculpt SPAC Deal For $1B Tumor Treatment Developer
• Judge Blasts J&J Unit For 'Tactical' Silence In Drug IP Fight
• 15 States Sign On To $4.5B Opioid Deal With Purdue
• Ex-JHL Biotech Execs Charged In $101M Wire Fraud Scheme
• Calif. Coroners Testify Opioid Death Causes Can Be Unclear
• NY Opioid Trial Dives Into History On 4th Day
• Theranos Judge Mulls WilmerHale's Role In Losing Key Data
• Boston Marriott Won't Get Early Win In Virus Coverage Row
• COVID Vaccine Vial Maker Leads Wave Of 5 IPO Launches
• McKool Smith Adds 2nd IP Litigator From Paul Hastings
• DC Circ. Won't Revisit Health Costs Ruling In Swinomish Suit
• Ethicon Says Fla. Pelvic Mesh Suit Was Filed Too Late
• NM AG's Suit Against Gilead, BMS Sent Back To State Court
• 5 Patent Cases To Watch In The Second Half Of 2021
• Pharmacist Linked To Deadly Outbreak Gets Extra 5 Years
• Rising Star: King & Spalding's Marisa Maleck
• Mass. Ruling A Cautionary Tale For Attorneys Changing Firms
• DOJ Should Weigh Dismissing Every Nonintervened FCA Suit
• Polish Drug Co. Says Trade Secret Fight Belongs In Arbitration
• Fed. Circ. Judge Unsure IP At Heart Of $1.1B Juno Win Is Valid
• Ill. Kickback Ruling Must Be Reconsidered, Court Told
• EU Remains A Holdout On COVID-Related IP Waiver At WTO
• The Term Finale: A 'Kumbaya Court'? Not So Fast
• Jones Day, Milbank Steer $1.7B Huntington Ingalls, Alion Deal
• DC Circ. Tosses FDA's Electric Shock Harnesses Ban
• Banner Witcoff Lands An IP Trial Pro From Morgan Lewis
• CMS Must Improve Diabetics' Access To Glucose Monitors
• The Biggest Patent Rulings Of 2021: A Midyear Report
• Rising Star: Kirkland & Ellis' Devora Allon
• The Sharpest Dissents From The Supreme Court Term
• Returning To Open Court: Excitement, Nerves And Extra Prep
• 3 Firms Build PE Swap For $5.25B Water Treatment Biz Solenis
• The Firms That Won Big At The Supreme Court
• Jury Convicts Medical Imaging CEO In $250M Health Fraud
• Brand Battles: Zynga Aims To Beat New 'With Friends' Game
• Miss. High Court Won't Reconsider Medical Pot Ruling
• Cannabis Bill Roundup: NC Advances Medical Pot Bill
• WTO Stresses Need For Better COVID-19 Trade Reporting
• Glenmark Wants Criminal Price-Fix Trial Cut Off From Teva's
• Justices Seemed Above The Political Fray, Until The Last Day
• Teva Sues Generics To Protect Huntington's Disease Drug
• Next Steps For Cos. After High Court Patent Assignor Ruling
• Rising Star: Skadden's Chadé Severin
• Orrick Nabs Ex-MoFo Life Sciences Atty In Silicon Valley
• CVS Persuades Justices To Review HIV Bias Case
• UK Litigation Roundup: Here's What You Missed In London
• Justices Agree To Review Medicare Reimbursement Programs
• Simpson, Kirkland Drive PE Purchase Of $8.5B Parexel
• How To Avert Media Narrative And Get A Fair High-Stakes Trial
• Servier Beats NHS' £220M Drug IP Suit At Top UK Court
• Retailers, Pharmacies Freed From Zantac Personal Injury MDL
• 1 Firm Edged Peers As June IPO Market Exploded
• Fed. Circ. Forecast: Kite Takes Aim At Juno's $1.2B IP Win
• Samsung Gets PTAB To Nix Image Sensor Patent Claims
• Fla. Employer Doesn't Have To Pay For Medical Pot Evaluation
• House Votes To Shield IGs, Allow Probes Of DOJ Attys
• A New Era For FDA Regulation Of Cell And Tissue Products
• Coronavirus Regulations: A State-By-State Week In Review
• Ad Dispute Process Does Not Boost Class Action Risk
• Breaking Down The Vote: The High Court Term In Review
• 6 Firms Assist As MKS Inks $6.5B Atotech Acquisition